Clinical study of febuxostat intervention in treatment of hyperuricemia and vascular endothelial dysfunction in patients with hyperlipidemia
10.3760/cma.j.issn.1674-6090.2017.05.015
- VernacularTitle:非布司他治疗高尿酸血症、高脂血症患者血管内皮功能损伤的临床研究
- Author:
Shifang CHEN
1
;
Yujia XU
;
Lijuan YIN
;
Yuanmiu TAO
;
Yu MEI
;
Youqing WANG
Author Information
1. 浙江省湖州市中心医院风湿免疫科
- Keywords:
Febuxostat;
Hyperuricemia;
Hyperlipidemia;
Vascular endothelial function
- From:
Chinese Journal of Endocrine Surgery
2017;11(5):409-413
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficiency of febuxostat on hyperuricemia and hyperlipidemia,provide evidences for the option of clinical treatment.Methods From Mar.2015 to Mar.2016,80 patients with hyperuricemia and hyperlipidemia were enrolled to this study,and they were randomly divided into observation group and control group by random number table,each group with 40 cases.The observation group received 40 mg of fenbuterol tablets once a day.The control group received 100 mg allopurinol tablets three times a day.The levels of serum uric acid,lipids,endothelium-soluble intercellular adhesion molecule-1 (sICAM-1) and endothelium (ET-1) were measured at the baseline,12 weeks after treatment and 24 weeks after treatment.Meanwhile,the liver and kidney function damage and adverse reactions were recorded.Results After treatment,the levels of uric acid,blood lipid,sICAM-1 and ET-1 were decreased in two groups,and there was significant difference between them (P＜0.05).The adverse effects of the two groups were transient.The incidence of liver or kidney damage,side effect of drug in observation group was lower than that in the control group,and there was no significant difference between the two groups (P＞0.05),except the incidence of rash.Conclusion Febuxostat intervention in treatment of patients with hyperuricemia and hyperlipidemia is safe and efficient.
